The preventive effect of Chinese herbal preparation Xuebijing against hyperactive inflammation after hepato-pancreato-biliary surgery

Abstract

Background

Hepato-pancreato-biliary (HPB) surgery is a primary treatment for benign and malignant diseases of the liver, biliary tract, and pancreas. Hyperactive inflammation has been indicated as a critical risk factor of post-operation death after HPB surgery. Xuebijing is an anti-inflammatory intravenous herbal preparation made from traditional Chinese medicines. Emerging evidence has implicated a protective role of Xuebijing against hyperactive inflammation.

Methods

A retrospective cohort study was conducted. We analyzed a total of 638 cases of HPB surgery, including hepatectomy, Whipple’s surgery, and surgeries for cholelithiasis, which were divided into a Xuebijing treatment group and a conventional treatment group according to whether they were treated with Xuebijing injection or not. Clinical data related to liver function and inflammation were compared between the two groups after operation, including liver function index, white blood cell (WBC) count, neutrophil percentage (NE%), C-reactive protein (CRP), serum interleukin-6 (IL-6), body temperature, mortality, incidence of adverse reaction, length of postoperative hospital stay, and hospitalization cost.

Results

Xuebijing injection was found to decrease the levels of inflammatory markers in the blood significantly, including WBC, NE%, CRP, IL-6, and reduce the incidence of postoperative fever without prolonging in-hospital length or increasing cost compared to the conventional treatment group. Moreover, our data demonstrated that Xuebijing injection did not impact liver function after hepatectomy.

Conclusions

These results suggest that Xuebijing injection alleviates hyperactive inflammation caused by HPB surgery, and support the application of Xuebijing injection as a safe therapeutic approach against hyperactive inflammation in patients with HPB surgery.

Introduction

Hepato-pancreato-biliary (HPB) surgery is one of the primary treatments for benign and malignant diseases of the liver, biliary tract, and pancreas (1,2). However, due to the complexity of the regional anatomy, intraoperative tissue damage (1,2) and gut microbial translocation (3) are nearly inevitable after HPB surgery. Therefore, systemic inflammation triggered by damaged tissue and bacterial translocation is a common complication after HPB surgery. Hyperactive inflammation that is aggravated from normal immune response to induce massive tissue injury may eventually cause systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) (4,5). Indeed, the emerging evidence has implicated hyperactive inflammation as a risk factor for postoperative complications and mortality after HPB surgery (6-10).

The pathogenic mechanism of hyperactive inflammation after HPB surgery has not yet been well studied. Damaged tissue and bacterial translocation during HPB surgery are considered as the main factors triggering the immune response (3,11). The massive tissue damage that frequently occurs in hemihepatectomy and Whipple’s surgery is critically involved in inducing hyperactive inflammation by upregulating proinflammatory cytokines and enhancing oxidative stress. Currently, effective therapy for hyperactive inflammation after HPB surgery is still lacking.

Anti-inflammation and antioxidative-stress treatments are considered to be the primary strategies for managing hyperactive inflammation (4). Xuebijing is an intravenous herbal preparation made from five traditional Chinese medicines: Chishao (Radix Paeoniae Rubra), Danggui (Radix Angelica Sinensis), Chuanxiong (Rhizoma Chuanxiong), Honghua (Flos Carthami), and Danshen (Radix Salviae Miltiorrhizae). Xuebijing injection, which has been widely used in China, has been shown to inhibit hyperactive inflammation, prevent oxidative stress, neutralize endotoxins, improve microcirculation (12-20). In clinical trials, Xuebijing was demonstrated to fine-tune immune response and alleviate SIRS and MODS in patients with sepsis (13,17,20) and severe burns (21). However, whether Xuebijing injection prevents hyperactive inflammation after HPB surgery remains unclear.

In this study, we investigated the efficiency of Xuebijing injection as a therapy for hyperactive inflammation after HPB surgery. Respectively, 426, 120, and 92 cases of hepatectomy, Whipple’s surgery, and surgeries for cholelithiasis were analyzed retrospectively. We found that Xuebijing injection significantly alleviates inflammation after HPB surgery, suggesting an important therapeutic effect of Xuebijing injection for hyperactive inflammation in patients after HPB surgery.

Methods

Patient selection

A total of 638 cases of HPB surgery occurring between January 2015 and September 2017 were analyzed, including hepatectomy, Whipple’s surgery, and surgeries for cholelithiasis. The inclusion criteria were as follows: (I) aged 18–75 years; (II) treated with partial hepatectomy, Whipple’s surgery, and surgery for cholelithiasis. The exclusion criteria were as follows: (I) presence of biliary obstruction; (II) preoperatively diagnosed with severe diseases of the heart, lung, kidney, or other organs, (III) data missing; (IV) previous abdominal surgery history; (V) unconscious patients; (VI) immunodeficiency. After the operation, 103, 60, and 46 cases were treated with Xuebijing injection, and 323, 60, and 46 cases were treated without Xuebijing injection in patients who underwent hepatectomy, Whipple’s surgery, and surgeries for cholelithiasis, respectively. For patients who underwent hepatectomy, the Xuebijing treatment group and the control group were further matched with a 1:1 propensity score and 202 patients were ultimately included in the study. Patient characteristic data are shown in Tables 1-3.

Table 1. Patient characteristics in the hepatectomy cohort.

Variables	Xuebijing group (n=101)	Control group (n=101)	P value
Age (y, $\overline{x}\pm s$)	51.9±9.8	53.9±11.2	0.175
Male (n, %)	83 (82.2%)	87 (86.1%)	0.441
Hepatitis (n, %)	92 (90.5%)	92 (90.5%)	1.000
Cirrhosis (n, %)	77 (76.2%)	75 (74.3%)	0.744
Laparoscopic (n, %)	7 (6.9%)	8 (7.9%)	0.788
Operation time (min, $\overline{x}\pm s$)	208.9±98.7	203.9±71.1	0.690
Hepatic inflow occlusion [min, M (r)]	0 [0–38]	0 [0–30]	0.308
Extensive liver resection (n, %)	53 (52.5%)	52 (51.5%)	0.888
Intraoperative blood loss (mL, $\overline{x}\pm s$)	270.9±248.0	237.7±228.4	0.334
ALT (U/L, $\overline{x}\pm s$)	38.6±36.6	38.3±31.9	0.960
AST (U/L, $\overline{x}\pm s$)	41.1±28.6	40.9±36.2	0.963
TBIL (μmol/L, $\overline{x}\pm s$)	12.8±7.0	13.0±6.2	0.821
WBC (×109/L, $\overline{x}\pm s$)	6.4±1.9	6.2±1.6	0.501
NE (%, $\overline{x}\pm s$)	58.3±10.1	58.6±12.9	0.866
Diameter of tumor (cm, $\overline{x}\pm s$)	5.9±3.7	5.4±3.2	0.444
Number of tumor [n, M (r)]	1 [1–4]	1 [1–4]	0.514
Child-Pugh A (n, %)	94 (93.1%)	97 (96.0%)	0.352

ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; WBC, white blood cell; NE%, neutrophil percentage.

Table 2. Patient characteristics in pancreaticoduodenectomy cohort.

Variables	Xuebijing group (n=60)	Control group (n=60)	P value
Age (y, $\overline{x}\pm s$)	53.7±9.1	51.8±9.6	0.553
BMI (kg/m2, $\overline{x}\pm s$)	21.6±7.4	21.1±8.9	0.314
Sex (n, %)			0.695
Male	40 (66.7%)	42 (70.0%)
Female	20 (33.3%)	18 (30.0%)
Background disease (n, %)
Hypertension	10 (16.7%)	6 (10.0%)	0.283
Diabetes	8 (13.3%)	6 (10.0%)	0.570
Operation time (min, $\overline{x}\pm s$)	400.9±176.8	413.5±143.1	0.098
Intraoperative blood loss (mL, $\overline{x}\pm s$)	217.1±162.3	200.0±126.9	0.306
Diameter of tumor [cm, M (r)]	2.5 (1.0–6.0)	2.25 (0.8–6.0)	0.804
WBC (×109/L, $\overline{x}\pm s$)	7.7±2.5	6.5±1.4	0.700
NE (%, $\overline{x}\pm s$)	67.6±8.8	61.6±8.8	0.973
CRP (mg/L, $\overline{x}\pm s$)	5.7±3.0	4.1±3.0	0.793

BMI, body mass index; WBC, white blood cell; NE%, neutrophil percentage; CRP, C-reactive protein.

Table 3. Patient characteristics in the cholelithiasis surgery cohort.

Variables	Xuebijing group (n=46)	Control group (n=46)	P value
Age (y, $\overline{x}\pm s$)	58.9±10.6	55.7±11.4	0.170
Male (n, %)	37 (80.4%)	34 (73.9%)	0.441
Operation time (min, $\overline{x}\pm s$)	180.1±81.0	176.6±71.1	0.554
Intraoperative blood loss [mL, M (r)]	35 [5–200]	50 [10–400]	0.490
WBC (×109/L, $\overline{x}\pm s$)	6.5±2.8	6.7±3.4	0.771
NE (%, $\overline{x}\pm s$)	61.1±11.1	59.1±16.9	0.500
ALT [U/L, M (r)]	50 [6–672]	40 [6–260]	0.607
AST [U/L, M (r)]	37 [10–649]	37 [12–242]	0.819
TBIL [μmol/L, M (r)]	19.0 [5.8-465.4]	16.4 [4.3-237.1]	0.563

ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; WBC, white blood cell; NE%, neutrophil percentage.

Xuebijing treatment

A Xuebijing injection of 50 mL was administrated 2 hours after surgery, and the treatment (50 mL, bid) continued for 5 days.

Clinical data

The clinical data collected included (I) the following general data: age, basic disease, preoperative levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TBIL), white blood cells (WBCs), neutrophil percentage (NE%), and C-reactive protein (CRP); (II) the surgical data collected including the following: surgical methods, operation duration, intraoperative blood loss; (III) the postoperative data collected including the following: pathological diagnosis, postoperative level ALT, AST, TBIL, WBC, NE%, CRP and body temperature, hospitalization cost, mortality, postoperative hospitalization days, and adverse drug reactions of Xuebijing.

Blood samples and serum interleukin-6 (IL-6) measurement

Blood samples were collected pre- and postoperatively at Nanfang Hospital Southern Medical University. All samples were collected in the morning before breakfast before surgery, and after surgery on postoperative day 3 at the hospital ward. Blood was drawn from the antebrachial vein into serum vacuum tubes. Serum samples were stored at 80 °C until assayed with IL-6 enzyme-linked immunosorbent assay (ELISA) kit (Abcam; Cambridge, MA, USA).

Statistical analysis

Statistical Product and Service Solutions 20.0 software were used for data analysis. The data of normal distribution were analyzed using two independent samples t-test and presented as $\overline{x}\pm s$. Data of skew distribution were analyzed with the rank-sum test and presented as M (range). The data between the two groups were compared using the chi-square test or Fisher’s exact test. P<0.05 was considered statistically significant.

Results

Xuebijing injection alleviates systemic inflammation without affecting liver function after hepatectomy

WBC, NE%, and CRP levels were analyzed to determine if Xuebijing injection alleviates systemic inflammation in patients undergoing hepatectomy. After hepatectomy, both WBC and NE% were increased on postoperative day 1 and started to recover on postoperative day 3 and 5 (Figure 1A,B). The CRP increased on postoperative day 1 and 3 and decreased on postoperative day 5 (Figure 1C). The CRP, WBC, and NE% on postoperative day 3 and/or 5 were significantly different between the Xuebijing injection group and the control group; Xuebijing injection significantly decreased CRP, WBC, and NE% on postoperative day 3 and/or 5 (Figure 1A,B,C). Levels of serum IL-6 were found to be significantly reduced by Xuebijing injection on postoperative day 3 (Figure 1D). The incidence of postoperative fever in Xuebijing group was significantly lower than that in the control group (Figure 1E). There was no significant difference in the length of postoperative hospital stay or hospitalization cost in the Xuebijing group compared with the control group (Figure 1F,G). Any symptoms that might be considered as side effects of Xuebijing injection were not found.

Figure 1.

Xuebijing injection alleviates systemic inflammation in patients after hepatectomy. (A,B,C) Levels of WBC (A), NE% (B), and CRP (C) in the Xuebijing injection group and control group. Xuebijing injection significantly lowered the levels of WBC, NE%, and CRP at POD 3 and POD 5; (D) levels of serum IL-6 measured by ELISA; (E) cumulative cases of fever 5 days after hepatectomy. Xuebijing injection significantly prevented fever; (F,G) length of postoperative hospital stay and cost; no significant difference was observed between the two groups. Data in A, B, C, E, F and G represent mean ± SD; n=101. The mean value was displayed. Data in D represent mean ± SD; n=10. *, P<0.05, **, P<0.01, ***, P<0.001. WBC, white blood cell; NE%, neutrophil percentage; CRP, C-reactive protein; IL-6, interleukin-6; ELISA, enzyme-linked immunosorbent assay; SD, standard deviation.

Liver function indices, including ALT, AST, and TBIL, were compared between the two groups to evaluate the effects of Xuebijing injection on postoperative liver dysfunction. The levels of ALT and AST in the two groups were significantly increased on postoperative day 1 and restored on postoperative day 3 and 5 (Figure 2). However, no significant difference in levels of ALT, AST, or TBIL was observed between the two groups (Figure 2). These results suggest that Xuebijing injection inhibits systemic inflammation without affecting liver function in patients after hepatectomy.

Figure 2.

Xuebijing injection does not alter liver function after hepatectomy. Levels of ALT (A), AST (B), and TBIL (C) in the Xuebijing injection group and control group. No significant difference was observed between the two groups. Data represent mean ± SD, n=101. The mean value was displayed. ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; SD, standard deviation.

Xuebijing injection suppresses systemic inflammation after pancreaticoduodenectomy

In patients who underwent Whipple’s surgery, the levels of CRP, WBC, and NE% in the two groups were increased on postoperative day 1 and recovered on postoperative day 3 and 5 (Figure 3A,B,C). The CRP, WBC, and NE% on postoperative day 1 and 3 were significantly lower in the Xuebijing injection group (Figure 3A,B,C). Levels of serum IL-6 were found to be significantly decreased by Xuebijing injection on postoperative day 3 (Figure 3D). The incidence of postoperative fever in Xuebijing group was significantly lower than that in the control group (Figure 3E). There was no significant difference in postoperative hospital stay or hospitalization costs in the Xuebijing group compared to the control group (Figure 3F,G). No perioperative deaths or side effects of Xuebijing injection were observed in the two groups. These data demonstrate that Xuebijing injection suppresses systemic inflammation in patients after pancreaticoduodenectomy.

Figure 3.

Xuebijing injection suppresses systemic inflammation after pancreaticoduodenectomy. (A,B,C) Levels of WBC (A), NE% (B), and CRP (C) in the Xuebijing injection group and control group. Xuebijing injection significantly decreased the levels of WBC, NE%, and CRP; (D) levels of serum IL-6 measured by ELISA; (E) cumulative cases of fever 5 days after pancreaticoduodenectomy. The incidence of postoperative fever was significantly lower in the Xuebijing group; (F,G) postoperative hospital days and cost; no significant difference was observed between the two groups. Data in A, B, C, E, F and G represent mean ± SD; n=101. The mean value was displayed. Data in D represent mean ± SD; n=10. *, P<0.05, **, P<0.01, ***, P<0.001. WBC, white blood cell; NE%, neutrophil percentage; CRP, C-reactive protein; IL-6, interleukin-6; ELISA, enzyme-linked immunosorbent assay; SD, standard deviation.

Xuebijing injection inhibits systemic inflammation in patients with cholelithiasis after surgery

In patients with cholelithiasis after surgery, levels of CPR, WBC, and NE% were elevated on postoperative day 1 and started to normalize on postoperative day 3 and 5 (Figure 4A,B,C). The CRP, WBC, and NE% on postoperative day 3 and 5 were significantly lower in the Xuebijing injection group (Figure 4A,B,C). Serum IL-6 was found to be significantly decreased by Xuebijing injection on postoperative day 3 (Figure 4D). There was no significant difference in the incidence of postoperative fever (Figure 4E), postoperative hospital stay, or hospitalization costs (Figure 4F,G). No side effects were observed in the Xuebijing injection group. These data indicate that Xuebijing injection prevents systemic inflammation in patients with cholelithiasis after surgery.

Figure 4.

Xuebijing injection inhibits systemic inflammation in patients with cholelithiasis after surgery. (A,B,C) Levels of WBC (A), NE% (B), and CRP (C) in the Xuebijing injection group and control group. Xuebijing injection significantly decreased the levels of WBC, NE%, and CRP; (D) levels of serum IL-6 measured by ELISA; (E) cumulative cases of fever 5 days after surgery for cholelithiasis. No significant difference was observed between the two groups; (F,G) postoperative hospital days and cost; no significant difference was observed between two groups. Data in A, B, C, E, F and G represent mean ± SD; n=101. The mean value was displayed. Data in D represent mean ± SD; n=10. *, P<0.05, ***, P<0.001. WBC, white blood cell; NE%, neutrophil percentage; CRP, C-reactive protein; IL-6, interleukin-6; ELISA, enzyme-linked immunosorbent assay; SD, standard deviation.

Discussion

HPB surgery is considered as the most challenging abdominal surgery and has an extreme impact on the patient’s physiology due to the complex procedures, large region of operation, long operation time, intraoperative tissue damage, and hyperactive inflammation after surgery. Although the development of surgical techniques and the improvement of surgical instruments have reduced the mortality of HPB surgery, the postoperative morbidity is still high (1,2). Hyperactive inflammation, which may eventually cause SIRI or MODS, is associated with postoperative morbidity and mortality (4). Thus, clinical efforts to effectively inhibit hyperactive inflammation after HPB surgery are crucial for reducing both postoperative morbidity and mortality. In this study, we retrospectively analyzed the outcome of Xuebijing injection in patients after HPB surgery and found that Xuebijing injection significantly alleviates inflammation after HPB surgery, including hepatectomy, Whipple’s surgery, and surgeries for cholelithiasis. Our study highlights the protective effect of Xuebijing injection against hyperactive inflammation after HPB surgery.

Xuebijing injection is a confidential national technology product made from several traditional Chinese medicines. Xuebijing injection is widely used in China to treat hyperactive inflammation (13,17,22). The mechanism by which Xuebijing injection inhibits hyperactive inflammation has been studied. Preliminary clinical studies have indicated that Xuebijing injection improves blood circulation to alleviate blood stasis and removes toxins (19,20). Liu et al. reported that Xuebijing treatment attenuated inflammation by decreasing pro-inflammatory cytokines IL-6, IL-13, and TNF-α, thus suppressing liver injury (23). Chen et al. also showed that Xuebijing treatment reduced oxidative stress and proinflammatory cytokines (24). Taken together, we can conclude that Xuebijing injection suppresses hyperactive inflammation after HPB surgery by possibly reducing proinflammatory cytokines, endotoxins, and oxidative stress.

Previous studies reported that Xuebijing injection has a hepatoprotective effect (16,23,25). Liu et al. reported that Xuebijing treatment suppressed liver injury by decreasing pro-inflammatory cytokines IL-6, IL-13, and TNF-α (23). Liu et al. showed that Xuebijing injection potently inhibited apoptosis and IL-1β production in isolated hepatocytes in an NF-κB-dependent manner, and also directly impacted hepatocyte inflammasome activation (16). Furthermore, a randomized controlled trial found that Xuebijing injection significantly decreased the levels of AST, ALT, and TBIL of patients in abdominal surgery (25). In our study on hepatectomy patients, compared with the control group, the Xuebijing group had lower levels of ALT, AST, and TBIL on postoperative day 1, 3, 5 but without a statistically significant difference. These resulted indicate that Xuebijing injection incurred no damage to liver function, and might have acted as a hepatoprotective treatment for the patients who underwent hepatectomy.

Several studies have reported the adverse effects caused by Xuebijing injection (13,14,17,25). Chest tightness, dyspnea, pruritus, and palpitations were the most common adverse effects. In this study, all patients were cured without perioperative death. Only three patients developed pruritus, and they were healed after withdrawing Xuebijing injection. Moreover, there was no significant difference in postoperative hospital stay or hospitalization costs in the Xuebijing group compared with the control group. These findings suggest that Xuebijing injection appears to be safe and feasible in patients after HPB surgery.

In conclusion, our study reveals that Xuebijing injection has profound anti-inflammatory and potential hepatoprotective effects on HPB surgery and can be safely applied to prevent and treat excessive inflammatory reactions after HPB surgery.

Ethical Statement: The authors are responsible for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study gained approval from the Institutional Review Board of Nanfang Hospital, Southern Medical University, and all participants signed written informed consent (No. NFEC-2017-119).